Nyumbani › Lupus Nephritis › Pennsylvania
Majaribio ya kliniki ya Lupus Nephritis katika jimbo la Pennsylvania
Masomo 7 ya Lupus Nephritis yanatafuta washiriki katika vituo vya jimbo la Pennsylvania.
Miji katika jimbo la Pennsylvania
Maandishi rasmi ya utafiti (Kiingereza)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Temple University, Philadelphia
InaajiriHatua 2
Umri 18 hadi 100 · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT05268289CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
- Children's Hospital of Philadelphia, Philadelphia
InaajiriHatua 1/2
Umri 10 hadi 29 · Jinsia zote · Imesasishwa 24 Sep 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
InaajiriHatua 2
Umri 16 hadi 70 · Jinsia zote · Imesasishwa 17 Sep 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 16 Sep 2026 · NCT05201469RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
InaajiriHatua 1/2
Umri 18 hadi 65 · Jinsia zote · Imesasishwa 26 Ago 2026 · NCT06121297PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Rheumatic Disease Associates, Ltd., Willow Grove
InaajiriHatua 4
Umri 18 hadi 75 · Jinsia zote · Imesasishwa 3 Ago 2026 · NCT07611214A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
InaajiriHatua 1
Umri 12 hadi 70 · Jinsia zote · Imesasishwa 22 Mei 2026 · NCT06308978Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.